Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareFirst Prescription Drug Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedCareFirstPolicy N/A

    Prescription Drug Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all CareFirst policy alerts

    Know when CareFirst releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage criteria for prescription and specialty drugs under CareFirst Medicare Advantage and Medicare Part D, including covered indications, clinical documentation, prerequisite therapy, prescriber requirements, age restrictions, coverage duration, and Part B versus Part D considerations.

    Policy Summary
    PayerCareFirst
    PolicyPrescription Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOctober 15, 2026
    Next Review DateN/A
    Key ActionSubmit the diagnosis confirmation, biomarker or mutation results, prior treatment history, disease stage, and treatment setting required for the requested drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Plan yearStandard approval duration
    3 monthsRSV vaccine authorization duration
    65+ yearsOlder-adult medication age threshold
    30 days/yearHigh-risk medication PA threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Part A/B exclusion
    Part D coordination rule
    Part B or DBenefit determination

    Drug-Specific Coverage Criteria

    Drug-Specific Medical Necessity and Indication Criteria

    Covered when the applicable product-specific indication, diagnostic, prior-treatment, prerequisite, and continuation requirements below are met.

    Cabometyx

    • For renal cell carcinoma, disease is advanced, relapsed, or stage IV, including brain metastases; for RET-positive NSCLC, disease is recurrent, advanced, or metastatic; for GIST, disease is residual, unresectable, preoperative/intraoperative tumor rupture, or recurrent/metastatic and progressed after at least two FDA-approved therapies; for Ewing sarcoma or osteosarcoma, use is subsequent therapy; for differentiated thyroid cancer, disease is locally advanced or metastatic, progressed after VEGFR-targeted therapy, and refractory or ineligible for radioactive iodine; for endometrial carcinoma, disease is recurrent and use is subsequent therapy.

    Cavhanza CML

    • For CML, diagnosis is confirmed by the Philadelphia chromosome or BCR-ABL gene; if resistant to an alternative tyrosine kinase inhibitor, the patient is negative for T315I, Y253H, E255K/V, and F359V/C/I mutations; and the patient has tried or is intolerant to generic nilotinib, cannot swallow solid oral dosage forms, or requires concurrent proton-pump-inhibitor or H2-receptor-antagonist therapy.

    CeQur initial therapy

    • The patient requires insulin management, is self-testing glucose, will be counseled to self-test, or uses continuous glucose monitoring, and has tried bolus injections without meeting glycemic goals or had difficulty administering multiple daily injections, or is unable to try bolus injections.

    Clomipramine

    • For OCD or panic disorder, inadequate response, intolerance, or contraindication to an SNRI or SSRI; for depression, inadequate response, intolerance, or contraindication to two of an SNRI, SSRI, mirtazapine, or bupropion; for anxiety, concurrent SSRI/SNRI use while it becomes effective or failure, intolerance, or contraindication to at least two SSRIs/SNRIs.
    • For patients age 65 or older, the prescriber must document that benefits outweigh risks and that concurrent anticholinergic or CNS-active medications are medically necessary when applicable.

    Cresemba

    • The requested drug is used orally; for invasive aspergillosis or fluconazole-refractory esophageal candidiasis in a patient with HIV, the patient has failed, cannot tolerate, or has a contraindication to voriconazole.

    Cystinosis diagnostic criteria

    • For cystinosis, diagnosis is confirmed by increased leukocyte cystine concentration, genetic testing, or corneal cystine crystals on slit-lamp examination; for Cystadrops and Cystaran, corneal cystine crystal accumulation is also present.

    Continuation therapy

    • When a product specifies continuation therapy, the patient must demonstrate clinical benefit, improvement, a positive response, decreased symptoms, normalized or improved laboratory values, or absence of unacceptable toxicity, as applicable to that product.

    Droxidopa

    • For initial therapy of neurogenic orthostatic hypotension, standing or head-up tilt testing shows a persistent decrease in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes; for continuation, symptoms have sustainably improved; the condition is associated with primary autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy.

    General drug-specific medical necessity

    • The requested drug is medically necessary for the documented diagnosis and indication, is prescribed within the product-specific indication and restrictions, and satisfies required prior therapy, laboratory, biomarker, age, route, specialist, duration, and continuation requirements.

    Everolimus indication-specific coverage

    • For breast cancer, disease is recurrent unresectable, advanced, or metastatic HR-positive/HER2-negative and everolimus is combined with exemestane, fulvestrant, or tamoxifen as subsequent therapy; for RCC, disease is relapsed, advanced, or stage IV; for SEGA, use is adjuvant; for GIST, disease has progressed after at least two FDA-approved therapies; for ECD, Rosai-Dorfman disease, or LCH, the patient has a PIK3CA mutation.

    Herceptin, Hercessi, related HER2 products, Kanjinti, Ogivri, and Ontruzant

    • For the listed trastuzumab products, the applicable disease must meet the product-specific HER2-positive or HER2-amplified criteria. For colorectal cancer, disease is HER2-amplified and RAS/BRAF wild-type with combination therapy and no prior HER2 inhibitor, or metachronous metastases; for hepatobiliary cancer, disease is HER2-positive, unresectable, gross residual, or metastatic and combined with pertuzumab or tucatinib; for endometrial cancer, combine with carboplatin and paclitaxel and continue as maintenance; for appendiceal cancer, disease is HER2-positive and RAS/BRAF wild-type with pertuzumab or tucatinib. Coverage is denied under Part D when Part A or Part B covers the administration.

    Hernexeos and Hyrnuo

    • For recurrent NSCLC, the tumor has a HER2/ERBB2 mutation and disease is recurrent, advanced, unresectable, or metastatic; for Hyrnuo, use is subsequent therapy and disease is recurrent, advanced, or metastatic.

    HRM products: amitriptyline, benztropine, desipramine, dipyridamole, doxepin, guanfacine, hydroxyzine, imipramine, and related products

    • For patients age 65 or older, the prescriber must acknowledge that benefits outweigh risks and that concurrent anticholinergic or CNS-active medications are medically necessary. Product-specific depression, anxiety, EPS, Parkinson disease, rhinitis, alcohol-withdrawal, and neuropathic-pain criteria require inadequate response, intolerance, contraindication, or required trials of the listed alternatives.

    Meclizine, phenobarbital, promethazine, cyclobenzaprine, and trimipramine

    • For patients age 65 or older, the prescriber must document that benefits outweigh risks and that concurrent anticholinergic or CNS-active medications are medically necessary. Promethazine requires trials of two listed non-HRM rhinitis alternatives; trimipramine requires trials and inadequate response or intolerance to two listed antidepressant alternatives.

    Icatibant hereditary angioedema

    • For acute HAE attacks, HAE with C1-inhibitor deficiency or dysfunction is laboratory-confirmed, or HAE with normal C1 inhibitor is laboratory-confirmed with a qualifying mutation or family history plus failure of at least one month of high-dose antihistamine therapy; prescriber is an immunologist, allergist, or rheumatologist.

    Iclusig oncology indications

    • For CML, the patient has accelerated or blast phase with no other indicated kinase inhibitor, chronic phase resistant or intolerant to at least two kinase inhibitors including imatinib, dasatinib, or nilotinib, T315I-positive disease, or no identifiable BCR-ABL1 mutation with resistance to specified primary therapies. For Ph-positive ALL, diagnosis is confirmed by the Philadelphia chromosome or BCR-ABL gene. For GIST, disease is residual, unresectable, recurrent, metastatic, or tumor rupture and progressed after at least two FDA-approved therapies.

    Idhifa AML and MDS

    • For AML, disease has an IDH2 mutation and is newly diagnosed in a patient unsuitable for or declining intensive induction, post-induction after response to lower-intensity therapy, relapsed or refractory, or being treated as consolidation; for MDS, disease has an IDH2 mutation.

    Imatinib disease-specific criteria and Imkeldi substitution

    • For CML or Ph-positive ALL, diagnosis is confirmed by the Philadelphia chromosome or BCR-ABL gene; for CML, prior tyrosine-kinase-inhibitor failure is excluded when failure was due only to intolerance. Disease-specific criteria apply for c-KIT-mutated melanoma, lymphoma, mastocytosis, eosinophilic neoplasms, desmoid tumors, PVNS/TGCT, chordoma, Kaposi sarcoma, and cGVHD. Imkeldi additionally requires inability to use imatinib tablets.

    Increlex initial and continuation therapy

    • For severe primary IGF-1 deficiency or GH gene deletion with neutralizing GH antibodies, initial therapy requires height at least 3 standard deviations below the age- and sex-adjusted mean, basal IGF-1 at least 3 standard deviations below the mean, and a normal or elevated provocative GH test; continuation requires improvement.

    Extended-release opioid criteria

    • Coverage requires cancer, sickle-cell, terminal, or palliative-care pain, or pain severe and persistent enough to require an opioid after alternatives including immediate-release opioids are inadequate; the dose is safe for the patient's opioid history, the patient is evaluated and monitored for opioid use disorder, and continuation requires at least 30 days of prior extended-release opioid therapy or at least one week of immediate-release opioid therapy.

    Itovebi, Orserdu, Veppanu, Verzenio, and TruQap breast cancer

    • The applicable breast cancer indication requires recurrent, locally advanced, advanced, metastatic, or unresectable disease; HR-positive and HER2-negative status when specified; required PIK3CA/AKT/PTEN or ESR1 mutation when specified; required combination therapy; and progression, recurrence, or prior endocrine or systemic therapy as specified for the product.

    Jakafi, Ojjaara, and Vonjo myelofibrosis

    • Disease must be primary or secondary myelofibrosis with the required risk category and symptoms. Ojjaara additionally requires anemia or transfusion dependence with inadequate response, intolerance, or contraindication to Jakafi, or hemoglobin below 8 g/dL; Vonjo requires qualifying risk and platelet count below 50,000/mcL or high-risk disease with splenomegaly or constitutional symptoms.

    Koselugo and Ojemda glioma criteria

    • For Koselugo, circumscribed glioma is recurrent or progressive with BRAF fusion, BRAF V600E mutation, or WHO grade 1 disease; NF-1-mutated glioma and pleomorphic xanthoastrocytoma are recurrent or progressive. For Ojemda, relapsed or refractory pediatric low-grade glioma has a BRAF fusion/rearrangement or BRAF V600 mutation.

    Lazcluze EGFR-mutated NSCLC

    • Disease is advanced, recurrent, or metastatic NSCLC with an EGFR exon 19 deletion or exon 21 L858R substitution mutation.

    Lenalidomide and Lenvima

    • For lenalidomide, disease-specific coverage includes lower-risk MDS with symptomatic anemia or MDS/MPN with SF3B1 mutation and thrombocytosis, together with the applicable approved or medically accepted indication. For Lenvima, differentiated thyroid cancer is not amenable to radioactive iodine and is unresectable, locally recurrent, persistent, or metastatic; RCC is advanced, relapsed, or stage IV; endometrial cancer is advanced, recurrent, or metastatic after systemic therapy; anaplastic thyroid cancer is metastatic and treated with pembrolizumab.

    Leukine, leuprolide, Lupron Depot-Ped, and lidocaine

    • For Leukine, chemotherapy is separated by at least 24 hours and febrile-neutropenia prophylaxis requires a non-myeloid cancer receiving myelosuppressive therapy. For leuprolide or Lupron Depot-Ped, central precocious puberty requires pubertal GnRH-test or LH evidence, bone-age support, and onset before age 8 in females or 9 in males. Topical lidocaine requires topical anesthesia use and FDA-approved topical active ingredients in compounded products; Part A/B coverage excludes Part D payment.

    Lonsurf, Lorbrena, Lumakras, and Lumizyme

    • Lonsurf requires advanced or metastatic colorectal disease with prior therapy, or unresectable locally advanced, recurrent, or metastatic gastric, esophageal, or gastroesophageal-junction cancer after at least two chemotherapy lines. Lorbrena requires ALK-positive or qualifying ROS1-positive NSCLC with the specified disease status and prior therapy. Lumakras requires recurrent, advanced, or metastatic KRAS G12C-positive NSCLC. Lumizyme requires enzyme or genetic confirmation of Pompe disease.

    Lynparza, Lytgobi, Mekinist, Mektovi, Monjuvi, and Metyrosine

    • Coverage requires the applicable biomarker, disease status, prior therapy, and combination or maintenance regimen. Lynparza prostate cancer requires BRCA/HRR-mutated disease and GnRH therapy or orchiectomy; Lytgobi requires FGFR2 fusion or rearrangement and previously treated unresectable or metastatic cholangiocarcinoma; Mekinist/Mektovi require qualifying BRAF disease and specified combination or subsequent therapy; Monjuvi requires relapsed, refractory, or progressive disease; Metyrosine requires inadequate response, intolerance, or contraindication to an alpha-adrenergic antagonist.

    Mounjaro, Naglazyme, Nitisinone, Nubeqa, Nuedexta, and Nuplazid

    • Mounjaro requires documented type 2 diabetes confirmed by qualifying A1C, fasting glucose, oral-glucose-tolerance, or symptomatic random-glucose criteria. Naglazyme requires enzyme or genetic confirmation of MPS VI. Nitisinone requires biochemical, genetic, or enzyme confirmation of HT-1. Nubeqa requires concurrent GnRH analog or bilateral orchiectomy. Nuedexta initial therapy requires diagnosed PBA with characteristic episodes and continuation requires fewer episodes. Nuplazid requires Parkinson disease diagnosed before psychotic symptoms for Parkinson disease psychosis.

    Omnipod initial therapy

    • The patient requires insulin management with multiple daily injections, self-tests glucose at least four times daily or uses continuous glucose monitoring, and, when the patient does not have type 1 diabetes, has inadequate control, recurrent hypoglycemia, wide glucose fluctuation, dawn phenomenon, or severe glycemic excursions on the current regimen.

    OpiPza indication-specific step therapy

    • For schizophrenia, MDD adjunctive therapy, autistic irritability, Tourette disorder, or schizoaffective disorder, the patient must fail, not tolerate, or have a contraindication to the applicable generic and brand alternatives, or be unable to swallow oral formulations.

    Orkambi, Orserdu, Ozempic, Pazopanib, Pemigatinib, Perampanel, sodium phenylbutyrate, and pimecrolimus

    • Orkambi requires cystic fibrosis and no concurrent CFTR potentiator. Orserdu requires ER-positive, HER2-negative, ESR1-mutated advanced or recurrent breast cancer and subsequent therapy. Ozempic requires documented type 2 diabetes with qualifying diagnostic testing. Pazopanib requires advanced, relapsed, or stage IV RCC or qualifying GIST after at least two therapies. Pemigatinib requires previously treated unresectable, gross residual, locally advanced, or metastatic FGFR2-rearranged cholangiocarcinoma. Perampanel requires failure, intolerance, or contraindication to a generic anticonvulsant and, for adults with focal seizures, Xcopri. Sodium phenylbutyrate requires enzymatic, biochemical, or genetic confirmation of a urea-cycle disorder. Pimecrolimus requires sensitive-area or failed first-line therapy use and short-term or intermittent use.

    Pirfenidone initial and continuation; Pomalidomide

    • Pirfenidone initial therapy requires exclusion of other causes of pulmonary fibrosis and HRCT, biopsy, or multidisciplinary evidence supporting IPF; continuation requires beneficial response. Pomalidomide for multiple myeloma requires at least one prior therapy or CNS involvement; other listed hematologic indications require the applicable approved or medically accepted indication.

    Qinlock, Infliximab, Retevmo, Rozlytrek, Rubraca, Rydapt, Sapropterin, Somatuline Depot, Sorafenib, Stivarga, and Synarel

    • Qinlock requires GIST after at least three kinase inhibitors including imatinib, or imatinib with intolerance to second-line sunitinib; KIT-mutated melanoma requires subsequent therapy after BRAF-targeted therapy. Infliximab requires indication-specific MTX, NSAID, biologic, phototherapy, or psoriasis criteria. Retevmo requires qualifying RET disease and disease status. Rozlytrek requires ROS1-positive NSCLC or NTRK-fusion solid tumor without an acquired resistance mutation. Rubraca requires BRCA/HRR or disease-specific criteria; Rydapt requires FLT3 or FGFR1 rearrangement criteria. Sapropterin requires pretreatment phenylalanine above 6 mg/dL initially and improvement on continuation. Somatuline acromegaly requires elevated IGF-1 and failed or unsuitable surgery/radiotherapy initially, with decreased or normalized IGF-1 on continuation. Sorafenib and Stivarga require the applicable advanced, recurrent, metastatic, or previously treated oncology indication. Synarel CPP requires qualifying GnRH/LH, bone-age, and age-of-onset criteria.

    Tafinlar, tasimelteon, Tecentriq, temazepam, Tavneos, terbinafine, testosterone, and tobramycin

    • Tafinlar requires the applicable BRAF V600 mutation and melanoma, NSCLC, thyroid, LCH, ECD, hairy-cell, or solid-tumor indication with required combination or disease status. Tasimelteon requires total blindness with inability to perceive light for non-24-hour sleep-wake disorder, or confirmed Smith-Magenis syndrome, plus continuation benefit. Tecentriq requires the applicable oncology disease, biomarker, stage, and regimen criteria. Temazepam requires short-term insomnia treatment, failure or contraindication to doxepin or ramelteon, and required geriatric risk documentation. Tavneos requires serologically confirmed ANCA vasculitis with adjunctive standard therapy and continuation benefit. Oral terbinafine requires oral, non-continuous treatment for dermatophyte onychomycosis. Testosterone requires two low morning testosterone levels initially and one confirmed pretreatment low level on continuation; gender dysphoria requires informed decision-making. Tobramycin requires Pseudomonas airway presence or history for cystic fibrosis or non-CF bronchiectasis.

    TruQap, Turalio, Uceris, Vanflyta, Velsipity, Venclexta, Veppanu, Versacloz, Verzenio, Vigabatrin, Vitrakvi, Vonjo, Voranigo, Vosevi, Vowst, Vyndamax, Vyvgart, Xifaxan, Xpovio, Xyrem, Zarxio, Zejula, Zelboraf, Zonisade, Ztalmy, Zurzuvae, Zymfentra, and Zyprexa Relprevv

    • Each product requires the applicable indication-specific disease status, biomarker, prior therapy, age, diagnostic, and regimen criteria. Xifaxan IBS-D requires no prior course or recurrent symptoms without exceeding one initial and two additional 14-day courses; SIBO requires recurrence after successful treatment or positive aspirate/breath testing. Xpovio requires at least one prior therapy for multiple myeloma or two systemic lines for B-cell lymphoma. Xyrem requires sleep-lab-confirmed narcolepsy, wakefulness-drug failure or contraindication for adult sleepiness, and continuation benefit. Zarxio requires chemotherapy timing of at least 24 hours and qualifying febrile-neutropenia risk. Vitrakvi requires NTRK-fusion solid tumor without known acquired resistance mutation. Voranigo requires IDH1/2-mutated oligodendroglioma, astrocytoma, or high-grade glioma after surgery or with residual, recurrent, or progressive disease. Vosevi requires HCV RNA confirmation and guideline-concordant regimen without decompensated cirrhosis. Vowst requires positive CDI testing and administration at least 48 hours after antibiotics. Vyndamax initial therapy requires symptomatic, objectively confirmed ATTR cardiomyopathy and continuation benefit. Vyvgart continuation requires no unacceptable toxicity and positive response. Zurzuvae requires standardized-scale confirmation of postpartum depression. Zyprexa Relprevv requires established oral olanzapine tolerability.

    Coverage is excluded or denied when the requested use is outside the applicable FDA-approved or medically accepted indication, when required biomarkers or diagnostic confirmation are absent, or when required prerequisite therapy has not been tried, is not contraindicated, or has not produced inadequate response or intolerance.

    Coverage under Part D is denied when the medication is prescribed, dispensed, or administered for an individual in a manner covered under Medicare Part A or Part B. Product-specific drug-interaction, hepatic impairment, disease, route-of-administration, and contraindication exclusions also apply, including avoidance of specified potent CYP3A4 inhibitors and contraindicated oral ketoconazole combinations.

    For androgen-dependent prostate cancer indications, the requested product must be used with a GnRH analog or after bilateral orchiectomy. For products requiring combination oncology therapy, the specified partner drug and treatment sequence must be documented.

    Clinical Thresholds and Operational Requirements

    Operational requirements must be documented in the prior-authorization request when applicable.

    Age and laboratory thresholds

    • Apply product-specific age limits, including CeQur and Mounjaro diabetes criteria, pimecrolimus age 2 years or older, icatibant age 18 years or older, Omnipod and CF product age requirements, and seizure-product age thresholds. Submit required laboratory values, including glucose or A1C, IGF-1 and GH testing, testosterone levels, IGF-1 for acromegaly, phenylalanine, blood pressure, platelet count, hemoglobin, ferritin, liver function, and disease-specific molecular or enzyme testing.

    Treatment intervals and authorization duration

    • Apply the stated product duration, including 14-day courses for IBS-D or SIBO, one month for Vowst or Zurzuvae, two months for initial Uceris or Sapropterin, three months for Droxidopa, Cresemba indications, or selected HRM products, six months for selected anti-infective, growth-factor, and tasimelteon initial therapies, and Plan Year for continuing oncology and chronic therapies.

    Prescriber and administration requirements

    Initial Authorization Criteria

    Drug-Specific Initial Authorization Framework

    Initial authorization requires all applicable drug-specific medical-necessity requirements, supported by clinical records and laboratory, diagnostic, biomarker, treatment-history, and prescriber information.

    Drug-specific initial authorization: The requested product is used for a listed indication and satisfies the applicable diagnosis, disease stage, biomarker or mutation, prior therapy, concurrent therapy, age, route, specialist, and safety requirements.
    Required clinical evidence: Submit disease confirmation, relevant laboratory or genetic testing, biomarker results, disease phase or stage, prior treatment history, intended regimen, and treatment setting when required.
    Prerequisite and specialist requirements: Document failure, intolerance, contraindication, or inability to use required prerequisite therapies and document specialist prescribing or consultation when specified.

    Continuation and Renewal Criteria

    Continuation Therapy Criteria

    Continuation authorization requires the patient to remain eligible for the indication and to demonstrate sustained benefit, objective improvement, response, or tolerability as specified below.

    Arcalyst: Fewer gout attacks or flare days than baseline are documented and urate-lowering therapy continues concurrently.
    Benlysta: The patient continues to receive benefit from therapy.
    Dalfampridine: Walking speed or another objective walking measure has improved since treatment began.
    Droxidopa: Symptoms of neurogenic orthostatic hypotension have been sustainedly reduced and the qualifying autonomic diagnosis remains present.

    Required Prior and Alternative Therapy

    Requested drug or indicationRequired prior therapy or sequenceFailure, intolerance, contraindication, or exception
    Arcalyst — new-start gout-flare prevention
    Prior maximum-tolerated NSAID and colchicine therapy; continue urate-lowering therapy concurrently
    Inadequate response, intolerance, or contraindication to both NSAID and colchicine; at least two gout flares in the prior 12 months
    Atovaquone — PCP treatment or primary prophylaxis
    Sulfamethoxazole/trimethoprim (SMX-TMP)
    Intolerance or contraindication to SMX-TMP; prophylaxis also requires immunocompromise
    Brivaracetam — partial-onset seizures
    Generic anticonvulsant; Xcopri when the patient is 18 years or older
    Inadequate response, intolerance, or contraindication to the applicable therapy
    Bysanti — schizophrenia or bipolar I manic/mixed episodes
    One listed generic antipsychotic followed by one listed brand antipsychotic
    Inadequate response, intolerance, or contraindication to both required products
    Cabometyx — GIST
    At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib
    Disease progression after the prior therapies; qualifying residual, unresectable, ruptured, recurrent, or metastatic disease also required
    Cabometyx — differentiated thyroid cancer
    Prior VEGFR-targeted therapy; radioactive iodine therapy when applicable
    Progression after VEGFR-targeted therapy and refractory or ineligible for radioactive iodine
    Calcipotriene or Enstilar — plaque psoriasis
    At least one topical corticosteroid
    Inadequate response or intolerance, or contraindication preventing a corticosteroid trial
    Cometriq — RET-positive NSCLC
    Pralsetinib or selpercatinib
    Disease progression after the prior RET-directed therapy
    Copiktra — CLL/SLL, breast implant-associated ALCL, or peripheral T-cell lymphoma
    Prior therapy as clinically indicated
    Disease must be relapsed or refractory; hepatosplenic T-cell lymphoma must be refractory
    Cresemba — invasive aspergillosis or fluconazole-refractory esophageal candidiasis in HIV
    Voriconazole
    Inadequate response, intolerance, or contraindication to voriconazole; oral use required
    Dasatinib — GIST
    Avapritinib
    Qualifying PDGFRA exon 18 mutation and residual, unresectable, recurrent/progressive, metastatic, or tumor-rupture disease
    Dasatinib — cutaneous melanoma
    Prior BRAF-targeted therapy
    Disease progression, intolerance, or risk of progression; metastatic or unresectable c-KIT-mutated disease required
    Emsam — major depressive disorder
    Two antidepressant classes or agents: an SNRI, SSRI, mirtazapine, or bupropion
    Inadequate response, intolerance, or contraindication to two options; exception if unable to swallow oral formulations
    Eprontia — focal-onset seizures
    Generic anticonvulsant and, for adults, Xcopri
    Inadequate response, intolerance, or contraindication to the applicable therapy
    Eprontia or topiramate — specified generalized seizures or migraine prevention
    Generic immediate-release topiramate
    Prior trial required unless the patient cannot swallow solid oral dosage forms
    Gilotrif — EGFR-positive NSCLC
    Erlotinib, gefitinib, or osimertinib
    Intolerable adverse event or contraindication; metastatic squamous NSCLC additionally requires progression after platinum chemotherapy
    Fanapt — schizophrenia or bipolar I disorder
    One listed generic antipsychotic followed by one listed brand antipsychotic
    Inadequate response, intolerance, or contraindication to both required products
    High-risk medications — depression indications
    Two SSRI, SNRI, bupropion, mirtazapine, or trazodone alternatives
    Inadequate response or intolerance to two alternatives
    Benztropine — extrapyramidal symptoms
    Amantadine
    Either contraindication without a trial or inadequate response/intolerance after a trial
    Benztropine — Parkinson disease
    Two of amantadine, carbidopa/levodopa, pramipexole, or ropinirole
    Inadequate response or intolerance to two alternatives
    Guanfacine ER or hydroxyzine — anxiety
    Two of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release
    Inadequate response or intolerance to two alternatives; acute anxiety permits an exception when two alternatives have not been tried
    Hydroxyzine — alcohol withdrawal syndrome
    Clorazepate or lorazepam
    Contraindication without a trial, or inadequate response/intolerance after a trial
    Zolpidem — insomnia
    Doxepin 3 or 6 mg or ramelteon
    Contraindication to both, or inadequate response/intolerance after trying one; applies to patients 65 years or older
    Promethazine — rhinitis
    Two of levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal
    Inadequate response or intolerance to two alternatives
    Iclusig — GIST
    At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib
    Disease progression after prior therapy; qualifying residual, unresectable, recurrent, metastatic, or tumor-rupture disease required
    Oncology indications with specified kinase-inhibitor sequencing
    Prior kinase inhibitors or other FDA-approved therapies specified for the requested indication
    Resistance, intolerance, progression, or failure as specified by the indication
    Inlurio or Itovebi — recurrent breast cancer
    At least one line of endocrine therapy
    Progression, relapse, or recurrence after endocrine therapy; Itovebi also requires the specified combination regimen
    Jakafi — polycythemia vera
    Hydroxyurea and, when applicable, Besremi
    Inadequate response, intolerance, or resistance to hydroxyurea; also inadequate response/intolerance to Besremi or high-risk disease
    Long-acting hydrocodone or morphine
    Extended-release opioid for at least 30 days or immediate-release opioid for at least one week
    Qualifying cancer, sickle-cell, terminal-condition, or palliative-care pain may qualify directly; otherwise alternatives, safe dosing, and monitoring are required
    Lorbrena — ROS1-rearrangement-positive NSCLC
    Crizotinib, entrectinib, repotrectinib, or taletrectinib
    Disease progression after the prior ROS1-directed therapy
    Lonsurf — colorectal or appendiceal adenocarcinoma
    Prior treatment; Lonsurf must be second-line or subsequent therapy
    Advanced or metastatic disease required
    Lonsurf — gastric, esophageal, or gastroesophageal junction adenocarcinoma
    At least two prior chemotherapy lines
    Unresectable locally advanced, recurrent, or metastatic disease required
    Megestrol acetate — adult cancer-related cachexia
    Megestrol 40 mg/mL oral suspension
    Inadequate response or intolerance
    Metyrosine
    Alpha-adrenergic antagonist
    Inadequate response, intolerance, or contraindication
    OpiPza — schizophrenia
    One listed generic and one listed brand antipsychotic
    Inability to swallow oral formulations is an alternative to both trials
    Orserdu — recurrent breast cancer
    Prior treatment; requested therapy is subsequent therapy
    ER-positive, HER2-negative, ESR1-mutated advanced, recurrent, metastatic, or preoperatively unresponsive disease required
    Pazopanib — GIST
    At least two FDA-approved therapies, or qualifying SDH-deficient GIST
    Disease must be residual, unresectable, recurrent/metastatic, or tumor rupture
    Perampanel — partial-onset seizures
    Generic anticonvulsant and, for adults, Xcopri
    Inadequate response, intolerance, or contraindication to the applicable therapy
    Pimecrolimus — atopic dermatitis
    At least one first-line therapy, such as a medium- or higher-potency topical corticosteroid, when sensitive-area criteria are not met
    Inadequate response, intolerance, or contraindication; sensitive-area disease is an alternative pathway
    Pomalidomide — multiple myeloma
    At least one prior therapy
    Prior therapy is not required when the disease has CNS involvement
    Quetiapine extended-release
    Indication-specific generic alternatives
    Inadequate response, intolerance, or contraindication; bipolar II depression requires immediate-release quetiapine trial or ineligibility
    Remicade or Renflexis — rheumatoid arthritis
    Methotrexate or a prior biologic or targeted synthetic DMARD
    Methotrexate intolerance/contraindication or inadequate response; prior biologic/targeted synthetic DMARD failure or intolerance
    Remicade or Renflexis — ankylosing spondylitis
    NSAID therapy
    Inadequate response or intolerance, or contraindication to an NSAID trial
    Remicade or Renflexis — plaque psoriasis
    Phototherapy, methotrexate, cyclosporine, or acitretin when severity requires prior therapy
    At least 3% BSA with inadequate response/intolerance or contraindication; at least 10% BSA may support biologic first-line therapy
    Qinlock — GIST
    At least three kinase inhibitors including imatinib, or imatinib followed by sunitinib
    Intolerance to second-line sunitinib when using the two-drug pathway
    Rubraca — metastatic castration-resistant prostate cancer
    Androgen receptor-directed therapy
    BRCA-mutated disease; use with a GnRH analog or after bilateral orchiectomy
    Rubraca — ovarian, fallopian tube, or primary peritoneal cancer maintenance
    Prior chemotherapy
    Stage II-IV or recurrent disease in complete or partial response to chemotherapy
    Sorafenib — GIST
    At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib
    Disease progression after prior therapy; qualifying residual, unresectable, ruptured, recurrent, or metastatic disease required
    Stivarga — colorectal cancer
    Lonsurf (trifluridine/tipiracil)
    Advanced or metastatic disease plus inadequate response, intolerance, or contraindication to Lonsurf
    Tadalafil — BPH
    Alpha blocker and 5-alpha reductase inhibitor
    Inadequate response, intolerance, or contraindication to both; erectile dysfunction is excluded
    Temazepam — short-term insomnia
    Doxepin 3 or 6 mg or ramelteon
    Inadequate response, intolerance, or contraindication; applies to patients 65 years or older
    Tafinlar — hairy cell leukemia
    Trametinib combination
    No prior BRAF inhibitor therapy
    Tofacitinib — new-start inflammatory conditions
    At least one TNF inhibitor
    Inadequate response, intolerance, or contraindication; continuation requires beneficial response
    Trintellix — major depressive disorder
    One generic SNRI, SSRI, mirtazapine, or bupropion
    Inadequate response, intolerance, or contraindication
    Truxima — rheumatoid arthritis new start
    Methotrexate or a prior biologic or targeted synthetic DMARD
    Methotrexate use or intolerance/contraindication plus inadequate response, intolerance, or contraindication to methotrexate or prior DMARD
    Ubrelvy — acute migraine
    At least one triptan 5-HT1 receptor agonist
    Inadequate response, intolerance, or contraindication
    Uceris — ulcerative colitis induction
    At least one 5-aminosalicylic acid therapy
    Inadequate response, intolerance, or contraindication
    Thalomid — chronic GVHD
    Corticosteroids, azathioprine, tacrolimus, cyclosporine, or other appropriate therapies
    Disease unresponsive to other therapies
    Acute migraine treatment
    At least one triptan 5-HT1 receptor agonist
    Inadequate response, intolerance, or contraindication
    Uceris — active mild-to-moderate ulcerative colitis
    At least one 5-aminosalicylic acid therapy
    Inadequate response, intolerance, or contraindication
    Versacloz — treatment-resistant schizophrenia
    At least one listed generic and one listed brand antipsychotic
    Inadequate response, intolerance, or contraindication to both required products
    Vigabatrin — complex partial seizures
    At least two antiepileptic drugs
    Inadequate response; age 2 years or older required for this indication
    Wyost or Xtrenbo — hypercalcemia of malignancy
    IV bisphosphonate therapy
    Refractory condition or clinical reason to avoid IV bisphosphonate therapy
    Xyrem — excessive daytime sleepiness in adults with narcolepsy
    At least one CNS wakefulness-promoting drug, such as armodafinil or modafinil
    Inadequate response or intolerance, or contraindication to a trial; sleep-lab-confirmed narcolepsy required
    Zonisade — adjunctive partial-onset seizures
    Generic anticonvulsant; Xcopri for patients 18 years or older
    Inadequate response, intolerance, or contraindication; difficulty swallowing solid oral dosage forms is an alternative

    Coverage Durations and Quantity Restrictions

    Coverage durations and course limits
    Abrysvo and Arexvy3 months coverage duration
    Albendazole6 months for hydatid disease or microsporidiosis; 1 month for all other indications
    Atovaquone6 months for toxoplasmosis or PCP prophylaxis; 3 months for all other indications
    High-risk medication productsPrior authorization applies to more than 30 cumulative days of therapy per year
    ZolpidemPrior authorization applies to more than 90 cumulative days of therapy per year
    Posaconazole DR3 months for treatment; 6 months for prophylaxis
    Xifaxan

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Drug-Specific Prior Authorization and Duration

    Drug-specific prior authorization is required for the applicable products and indications in this schedule. Submit the requested indication, clinical rationale, prerequisite-treatment history, relevant diagnostic findings, and treatment setting.

    • Drug-specific prior authorization: PA applies by drug, indication, and coverage criteria; prerequisite therapy is required when identified in the drug-specific criteria.
    • Berinert: prescribe by or in consultation with an immunologist, allergist, or rheumatologist.
    • Coverage duration varies by drug: approvals may be for a plan year, a specified number of months, or a defined initial/continuation period; apply the drug-specific duration.
    • High-risk medications: attest that benefits outweigh risks when required, document multiple anticholinergic or CNS-active medication review, and observe duration thresholds, including the zolpidem annual limit.
    • Part D coordination: Part D coverage may be denied when Part A or Part B coverage is available or responsible for the medication as prescribed, dispensed, or administered.

    Clinical Thresholds and Operational Values

    Numeric thresholds and timing requirements
    Prolastin-C alpha1-proteinase inhibitor levelLess than 11 micromol/L; equivalent to less than 80 mg/dL by radial immunodiffusion or less than 50 mg/dL by nephelometry
    Ayvakit systemic mastocytosis platelet countAt least 50,000/mcL
    Arcalyst gout historyAt least 2 gout flares within the previous 12 months
    Droxidopa orthostatic blood-pressure decreaseAt least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing or head-up tilt
    Increlex growth criteriaHeight and basal IGF-1 at least 3 standard deviations below the mean for children of the same age and gender; provocative growth hormone level normal or elevated
    Type 2 diabetes diagnostic valuesHbA1c at least 6.5%; two fasting plasma glucose levels at least 126 mg/dL; 2-hour glucose at least 200 mg/dL; or random glucose at least 200 mg/dL with classic symptoms or hyperglycemic crisis

    Clinical Terms and Abbreviations

    Clinical and molecular definitions
    GnRHGonadotropin-releasing hormone; the policy requires a GnRH analog or bilateral orchiectomy for selected prostate-cancer therapies.
    RETRearranged during transfection; a molecular alteration used to identify qualifying NSCLC for selected therapies.
    ALK-positive NSCLCAnaplastic lymphoma kinase-positive non-small cell lung cancer identified by ALK status.
    HER2/ERBB2Human epidermal growth factor receptor 2, also referred to as ERBB2.
    HAEHereditary angioedema caused by deficient or dysfunctional C1 inhibitor, or normal-C1-inhibitor HAE meeting specified genetic or clinical criteria.
    Ph+ ALLAcute lymphoblastic leukemia associated with the Philadelphia chromosome or BCR-ABL gene.

    Administration, Dispensing, and Benefit Determination

    Billing Rule

    Confirm site of care and Part B versus Part D responsibility

    Confirm the site of care and benefit category before billing or submitting the request. Coverage may fall under Medicare Part B or Part D depending on how the drug is used and the setting in which it is dispensed or administered; submit use and setting information when needed.

    • Arikayce must be prescribed by or in consultation with a pulmonologist, infectious disease specialist, or prescriber specialized in Mycobacterium avium complex lung disease.
    • Cresemba must be used orally.
    • For drugs that may be covered under Part B or Part D, describe the administration setting and intended use.

    Biosimilar and Product-Specific Requirements

    Billing Rule

    Align biosimilar use and benefit responsibility

    For the listed HER2 products, confirm that the requested product aligns with the applicable HER2 indication, biomarker, disease extent, combination regimen, and Part D eligibility criteria. When switching from Trazimera to a listed product such as Kanjinti, document an intolerable adverse event that was not attributed to the active ingredient; Part D coverage is denied when Part A or Part B coverage applies.

    • Document HER2 or HER2/ERBB2 status and the eligible disease setting.
    • Include the required combination regimen and prior-treatment history.
    • For Kanjinti, document the qualifying Trazimera adverse event and confirm Part A/B responsibility before billing.

    Policy Scope and Context

    This document is a drug-level prior authorization schedule for CareFirst Medicare Advantage and Medicare Part D prescription and specialty drugs. It spans multiple clinical specialties, including oncology and hematology, rare diseases and enzyme replacement, infectious disease, neurology and psychiatry, inflammatory and autoimmune conditions, pulmonary medicine, dermatology, endocrinology, and other specialty-drug services. Each listed product is evaluated according to its indication, required clinical information, prerequisite therapy, age or prescriber restrictions, coverage duration, and applicable Part A, Part B, or Part D benefit rules.

    Policy Summary
    PayerCareFirst
    PolicyPrescription Drug Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOctober 15, 2026
    Next Review DateN/A
    Key ActionSubmit the diagnosis confirmation, biomarker or mutation results, prior treatment history, disease stage, and treatment setting required for the requested drug.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaInitial Authorization CriteriaContinuation and Renewal CriteriaRequired Prior and Alternative TherapyCoverage Durations and Quantity RestrictionsPrior Authorization and Documentation RequirementsClinical Thresholds and Operational ValuesClinical Terms and AbbreviationsAdministration, Dispensing, and Benefit DeterminationBiosimilar and Product-Specific RequirementsPolicy Scope and Context
    When specified, treatment must be prescribed by or in consultation with the relevant specialist, including pulmonology, infectious disease, allergy/immunology, rheumatology, endocrinology, oncology, hematology, gastroenterology, metabolic disease, neurology, psychiatry, sleep medicine, or cystic-fibrosis specialists. Document oral, intravenous, topical, inhaled, or combination administration requirements and chemotherapy timing of at least 24 hours when applicable.

    Migraine prerequisite

    • For acute migraine products, the patient has experienced inadequate response, intolerance, or contraindication to at least one triptan 5-HT1 receptor agonist.

    Androgen-deprivation combination requirement

    • Abiraterone, Erleada, Lynparza when required for prostate cancer, Nubeqa, Rubraca, Xtandi, Yonsa, and other specified androgen-receptor or PARP products require concurrent GnRH analog therapy or prior bilateral orchiectomy.

    CNS cancer, melanoma, Erdheim-Chester disease or Langerhans cell histiocytosis, and NSCLC

    • CNS cancer criteria require the specified BRAF or IDH alteration and the required combination, postoperative, recurrent, progressive, or adjuvant setting. Melanoma criteria require the specified BRAF or KIT alteration and unresectable, limited-resectable, metastatic, adjuvant, neoadjuvant, or subsequent-therapy setting. ECD or LCH criteria require the specified BRAF, ALK, CSF1R, or PIK3CA alteration, with symptomatic or relapsed/refractory disease when stated. NSCLC criteria require the specified ALK, ROS1, RET, EGFR, HER2, MET, KRAS, NTRK, or BRAF alteration and recurrent, advanced, unresectable, or metastatic disease when required.
    paragraphs

    Initial Therapy Criteria

    For initial therapy, coverage requires the applicable pathway below. Where an indication has multiple alternatives, at least one qualifying pathway must be met; requirements joined by “and” are cumulative.

    Dalfampridine: For multiple sclerosis, sustained walking impairment is demonstrated before initiation.
    Droxidopa: Persistent orthostatic reduction of at least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing or tilt is documented, and the patient has a qualifying autonomic disorder.
    Ensacove: Recurrent, advanced, or metastatic ALK-positive NSCLC is documented, with no prior ALK inhibitor or intolerance/progression with crizotinib.
    Fabrazyme: Fabry disease is confirmed by deficient alpha-galactosidase activity, genetic testing, or symptomatic obligate-carrier status; patient is at least 2 years old and specialist involvement is documented.
    Haegarda or Icatibant: Qualifying HAE with C1-inhibitor deficiency/dysfunction is laboratory-confirmed, or normal-C1-inhibitor HAE meets the specified mutation or family-history and antihistamine-refractory pathway; applicable age and specialist requirements are met.
    Gattex: The patient has short bowel syndrome and is dependent on parenteral support; required gastrointestinal or nutritional-support specialist involvement is documented.
    Fruzaqla: Advanced or metastatic colorectal or appendiceal adenocarcinoma is documented, the drug will be used as a single agent, and it is second-line or subsequent therapy.
    HER2 products: The patient has the applicable HER2-positive or HER2-amplified disease, disease extent, biomarker status, prior-treatment history, and required combination regimen; for specified biosimilars, an intolerable Trazimera adverse event not attributed to the active ingredient is documented.
    High-risk medications: The patient is at least 65 years old, the prescriber documents that benefits outweigh risks, and the required alternative therapy, contraindication, inadequate response, intolerance, or concomitant-medication criteria are satisfied.
    Iclusig: The patient meets the disease-specific CML, Philadelphia-positive ALL, or GIST pathway, including required molecular confirmation, prior kinase-inhibitor history, or progression after at least two FDA-approved therapies.
    Increlex: For severe primary IGF-1 deficiency or GH gene deletion with neutralizing GH antibodies, height and basal IGF-1 are at least 3 standard deviations below the mean and provocative growth hormone testing is normal or elevated.
    Nuedexta: Pseudobulbar affect is caused by underlying neurologic disease or injury and includes involuntary, sudden, frequent laughing or crying episodes.
    Mresvia: The patient has not previously received Abrysvo, Arexvy, or Mresvia.
    Omnipod: The patient requires multiple daily insulin injections and tests glucose at least four times daily or uses CGM; if the patient does not have type 1 diabetes, a qualifying glycemic problem is documented.
    Pirfenidone: Other causes of pulmonary fibrosis are excluded and HRCT, biopsy, or multidisciplinary review supports UIP, probable UIP, or indeterminate UIP consistent with IPF.
    Pimecrolimus: Mild-to-moderate atopic dermatitis affects sensitive areas, or there is inadequate response, intolerance, or contraindication to at least one first-line topical therapy; use is short-term or non-continuous.
    Posaconazole and Prevymis: Posaconazole is used orally in a patient at least 2 years old and weighing more than 40 kg. Prevymis meets the applicable CMV-serostatus and HSCT or kidney-transplant pathway and age requirement.
    Infliximab products: For rheumatoid arthritis, the methotrexate and DMARD pathway is met; for ankylosing spondylitis, NSAID failure, intolerance, or contraindication is documented; for psoriasis, the crucial-area, 10% BSA, or 3% BSA with failed/contraindicated therapy pathway is met; for hidradenitis or uveitis, the specified severity or immunosuppressive-therapy pathway is met.
    Rubraca and Somatuline Depot: Rubraca meets the indication-specific BRCA, prior-therapy, metastatic, or maintenance pathway. Somatuline Depot initial acromegaly therapy requires elevated pretreatment IGF-1 and inadequate or unavailable surgery/radiotherapy.
    Synarel and Tasimelteon: Synarel CPP requires GnRH testing or pubertal LH, supportive bone age, and early secondary sexual characteristics. Tasimelteon requires total blindness and inability to perceive light for Non-24, or confirmed Smith-Magenis syndrome; age limits apply.
    Tavneos and testosterone: Tavneos requires anti-MPO or anti-PR3-confirmed severe ANCA-associated vasculitis and adjunctive standard therapy. Initial testosterone therapy requires at least two confirmed low morning total testosterone concentrations; gender dysphoria requires ability to make an informed decision.
    Treprostinil: WHO Group 1 PAH is confirmed by right-heart catheterization and new-start hemodynamic thresholds are met: mPAP >20 mmHg, PCWP <=15 mmHg, and PVR >2 Wood units.
    Zonisade and Zyprexa Relprevv: Zonisade requires generic anticonvulsant and, when age 18 or older, Xcopri failure, intolerance, or contraindication, unless difficulty swallowing solid dosage forms applies; the patient is at least 16 years old. Oral olanzapine tolerability is established before Zyprexa Relprevv.
    Gattex: Parenteral-support requirements have decreased from baseline while receiving Gattex.
    Fentanyl patch: Severe persistent pain continues to require extended opioid treatment; dosing remains safe, opioid-use-disorder monitoring continues, and required prior opioid exposure is documented.
    Increlex: The patient is experiencing clinical improvement.
    Nuedexta: Pseudobulbar affect episodes have decreased since starting therapy.
    Pirfenidone: The patient demonstrates beneficial response, such as slowing of clinical decline.
    Infliximab products: The patient has achieved or maintained a positive clinical response.
    Sapropterin: The therapeutic trial produced improvement, such as reduced phenylalanine or improved neuropsychiatric symptoms.
    Somatuline Depot: IGF-1 has decreased or normalized since therapy began.
    Tasimelteon: For Non-24, nighttime sleep has increased or daytime naps have decreased; for Smith-Magenis syndrome, sleep quality has improved.
    Tavneos: The patient has experienced benefit from therapy for severe ANCA-associated vasculitis.
    Testosterone: For hypogonadism, a low morning testosterone concentration was documented before therapy; for gender dysphoria, the patient remains able to make an informed decision regarding hormone therapy.
    Tofacitinib and Tyenne: The patient has experienced a beneficial response to therapy.
    Velsipity: For moderately to severely active ulcerative colitis, the patient has experienced a beneficial response.
    Vyndamax: The patient demonstrates beneficial response, such as slowing of clinical decline.
    Vyvgart: There is no unacceptable toxicity on the current regimen and the patient has demonstrated a positive response.
    Xyrem: Daytime sleepiness or cataplexy episodes have decreased.
    Zymfentra: For moderately to severely active ulcerative colitis or Crohn's disease, the patient has achieved or maintained a positive clinical response.
    One initial 14-day course and two additional 14-day courses for IBS-D; recurrent-course rules apply
    Step Therapy

    Product-Specific Prerequisites and Safety Attestations

    Submit product-specific prerequisites and clinical evidence before requesting authorization. The following products require indication-specific sequencing, biomarker, diagnostic, laboratory, safety, or continuation documentation.

    • Topical and dermatologic therapy: Calcipotriene and Enstilar require an inadequate response, intolerance, or contraindication to a topical corticosteroid; pimecrolimus requires appropriate first-line therapy and short-term or non-continuous use; topical clindamycin requires intolerance to formulary clindamycin lotion, solution, or twice-daily gel.
    • Neurologic and seizure therapy: Brivaracetam, Eprontia, perampanel, and Zonisade require inadequate response, intolerance, or contraindication to a generic anticonvulsant and, when applicable, Xcopri; Eprontia also requires generic topiramate immediate-release trial or inability to swallow solid dosage forms for specified indications.
    • Psychiatric therapy: Clomipramine, Drizalma Sprinkle, Emsam, Exxua, Fetzima, Trintellix, Fanapt, Bysanti, and Opipza require the specified antidepressant or antipsychotic alternatives and sequencing. Clomipramine additionally requires geriatric benefit-risk and multiple-anticholinergic/CNS medication attestations; apply sequential antipsychotic trials, depression alternatives, EPS/Parkinson’s alternatives, anxiety alternatives, and alcohol-withdrawal alternatives where applicable.
    • Cardiovascular, sleep, and symptom therapy: Diazepam requires geriatric benefit-risk and anxiety criteria; temazepam requires older-adult safety acknowledgment and doxepin or ramelteon trial; DHE nasal and ergotamine require a triptan trial; droxidopa requires initial orthostatic testing and continuation response; tasimelteon requires the qualifying indication and response; tadalafil for BPH excludes erectile dysfunction and requires alpha-blocker and 5-ARI step therapy.
    • Endocrine and supportive therapy: CeQur requires insulin-management eligibility and glucose-monitoring documentation; Increlex requires baseline height, IGF-1, and growth-hormone measurements; Metyrosine requires prior alpha-adrenergic antagonist therapy; testosterone requires laboratory confirmation and, for gender dysphoria, informed decision-making; Trulicity requires type 2 diabetes diagnostic confirmation.
    • Specialty products: Leqembi maintenance requires at least 18 months of IV lecanemab; Megestrol suspension requires inadequate response or intolerance to megestrol 40 mg/mL suspension; Cresemba requires oral use and voriconazole prerequisite where applicable; flucytosine requires oral route and indication-specific duration; terbinafine is limited to restricted, non-continuous duration.
    Prior Authorization

    Oncology, Infectious Disease, Neurologic, and Specialty Authorization

    For oncology and specialty drugs, submit the disease stage, treatment history, molecular findings, regimen, and required specialist documentation. Authorization depends on the product-specific disease, biomarker, sequencing, and combination rules.

    • CML, leukemia, and hematologic products: Cavhanza and Danziten require Philadelphia chromosome/BCR-ABL confirmation and applicable mutation and prior-nilotinib criteria; Dasatinib requires hematologic or solid-tumor diagnosis, molecular findings, and applicable prior therapy; Daurismo requires AML phase, age/comorbidity, low-dose cytarabine combination, and induction or post-induction use; Rubraca requires CML molecular findings, treatment history, and mutation exclusions; Iclusig requires qualifying CML/ALL or GIST disease and prior kinase-inhibitor history; Vanflyta requires FLT3-ITD mutation and AML disease phase; Vonjo requires myelofibrosis risk and platelet or symptom criteria.
    • Solid-tumor oncology: Cometriq requires RET-positive NSCLC with progression after pralsetinib or selpercatinib; Copiktra requires relapsed or refractory disease; Cotellic requires BRAF V600 mutation and vemurafenib combination; Erivedge requires prior systemic therapy and sonic-hedgehog pathway mutation for adult medulloblastoma; Erleada and Nubeqa require androgen-deprivation therapy or orchiectomy; Erlotinib, Gefitinib, and Gilotrif require the specified EGFR-positive NSCLC disease and treatment prerequisites; Everolimus requires indication-specific disease, combination, and prior-treatment criteria; Fotivda requires advanced/relapsed/refractory or stage IV RCC and at least two prior systemic therapies; Fruzaqla requires advanced/metastatic colorectal or appendiceal disease and second-line or later single-agent use.
    • RET, MET, ALK, HER2, and biomarker-directed therapy: Ensacove requires ALK-positive recurrent/advanced/metastatic NSCLC and specified ALK-inhibitor history; Gavreto requires RET-positive NSCLC; Tepmetko requires MET exon-14 skipping mutation; Tafinlar requires BRAF V600 mutation and applicable regimen; HER2-directed therapy requires the documented HER2 indication, tumor, regimen, and treatment history. Hernexeos requires HER2-mutated recurrent/advanced/unresectable/metastatic NSCLC; Trazimera, Tukysa, and related HER2 products require tumor and combination criteria; HER2 requirements not met are a denial risk.
    • Additional oncology sequencing: Cabometyx has indication restrictions and requires clinical documentation and, for GIST, prior FDA-approved therapies; Stivarga requires prior treatment and Lonsurf failure for colorectal cancer; Sorafenib requires oncology authorization and prior GIST treatment history; Lonsurf requires prior chemotherapy; Qinlock requires GIST treatment history; Nerlynx requires prior trastuzumab-based therapy or the specified prior therapies; Inlurio requires endocrine therapy; Itovebi requires prior endocrine therapy; Jakafi requires hydroxyurea/Besremi sequencing for polycythemia vera; Lorbrena requires prior ROS1-directed therapy when applicable; oncology prior-treatment requirements apply to the listed products and indications.
    • Other specialty indications: Filspari requires biopsy-confirmed IgA nephropathy and RAS-inhibitor history; Gattex requires short bowel syndrome with parenteral-support documentation and continuation reduction; Filspari, Pirfenidone, Pulmozyme, and Signifor require the applicable specialist involvement; Thalomid requires chronic GVHD and prior-therapy failure; Tobramycin requires Pseudomonas evidence; Tofacitinib and Tyenne require prerequisite therapy and continuation response; Treprostinil requires pulmonary-hypertension hemodynamic criteria; Zymfentra requires continuation response; Zurzuvae requires postpartum-depression documentation.
    Documentation Required

    Clinical Documentation, Specialists, and Continuation Evidence

    Requests must identify the treating specialist, prerequisite therapy, disease stage, diagnostic confirmation, laboratory or biomarker findings, and initial-versus-continuation status. Continuation requests generally require objective clinical benefit or response.

    • Specialist involvement: Cystic-fibrosis products require CF specialist or pulmonology involvement where specified; IPF products require pulmonology/IPF specialist involvement; Pulmozyme requires pulmonologist or CF specialist; Pirfenidone requires pulmonologist or IPF specialist; Signifor requires endocrinologist; Gattex requires gastroenterologist, GI surgeon, or nutrition-support specialist; Haegarda and Icatibant require immunologist, allergist, or rheumatologist involvement; Xyrem requires sleep specialist or neurologist involvement.
    • Continuation response: Dalfampridine requires improved walking speed or objective walking ability; Droxidopa requires sustained symptom reduction; Pirfenidone requires beneficial response; Sapropterin requires improved phenylalanine or neuropsychiatric measures; Tasimelteon requires improved sleep; Tofacitinib, Tyenne, Truxima, and Zymfentra require beneficial or positive clinical response; Gattex requires reduced parenteral-support need; Zurzuvae requires documented postpartum-depression diagnosis before the short course.
    • Diagnostic and laboratory evidence: Cerezyme and Cerdelga require enzyme or genetic confirmation of Gaucher disease; Fabrazyme requires alpha-galactosidase deficiency or genetic confirmation; Cystagon and ocular cystinosis therapy require cystinosis confirmation by leukocyte cystine, genetic testing, or slit-lamp crystals; Alpha1-proteinase inhibitor therapy requires emphysema and deficient serum level; Deferasirox requires ferritin above 1000 mcg/L; Vonjo requires disease and platelet/laboratory criteria; testosterone requires confirmed low morning testosterone; Treprostinil requires right-heart catheterization and pulmonary-hemodynamic findings.
    • Clinical documentation: submit Cabometyx documentation, disease and treatment evidence, use and setting information, oncology biomarker documentation, Iclusig oncology documentation, Imatinib and Imkeldi documentation, Increlex baseline measurements, Ketoconazole risk-benefit and indication documentation, hepatitis C treatment documentation for Mavyret/Vosevi, IPF diagnostic documentation, insulin-pump eligibility documentation, pulmonary-hypertension documentation, interstitial-lung-disease documentation, Vyndamax ATTR-CM documentation, Xyrem narcolepsy documentation, Zarxio/Leukine chemotherapy documentation, Synarel central-precocious-puberty documentation, Tavneos vasculitis documentation, and postpartum-depression diagnostic scale results.
    • Diabetes and pump records: submit type 2 diabetes records and laboratory confirmation, including A1C, fasting glucose, oral-glucose-tolerance, or qualifying random glucose results; submit insulin-pump eligibility and glucose-monitoring records for CeQur and Omnipod.
    • Timing and route: document Flucytosine route and duration, Cresemba route and duration restrictions, chemotherapy timing for Fulphila, Leukine, and Zarxio, and the required treatment setting for Part A/B determinations.
    Step Therapy

    Step Therapy, Interactions, and Prior Treatment

    Step therapy and interaction review must be completed before submission. Include failed, intolerant, contraindicated, or unsuitable therapies and document any exception such as inability to swallow solid dosage forms.

    • Required prerequisite therapy: document drug-specific prerequisite therapy, including topical corticosteroids; generic anticonvulsant and Xcopri; generic topiramate; triptans; antidepressants; antipsychotics; alpha blockers and 5-ARIs; 5-ASA; TNF inhibitors; DMARDs; infliximab or other biologic therapy; endocrine therapy; chemotherapy; kinase inhibitors; HER2-directed therapy; prior ROS1-directed therapy; prior EGFR inhibitor; prior GIST therapy; and prior chronic-GVHD therapy.
    • Sequencing examples: Arcalyst requires inadequate response, intolerance, or contraindication to NSAID and colchicine for gout-flare prevention; Atovaquone requires SMX-TMP intolerance or contraindication where specified; Brivaracetam and Eprontia require anticonvulsant step therapy; Bysanti and Fanapt require sequential generic and brand antipsychotic trials; Opipza requires generic and brand antipsychotic alternatives by indication; Quetiapine requires generic alternatives; Lonsurf, Stivarga, Cabometyx, Qinlock, Rubraca, and oncology products require the applicable prior-treatment sequence.
    • Alternative therapy pathways: document depression alternatives, EPS and Parkinson’s alternatives, anxiety alternatives, alcohol-withdrawal alternatives, insomnia alternatives, rhinitis alternatives, Pimecrolimus first-line therapy, tadalafil BPH prerequisite therapy, Temazepam insomnia prerequisite therapy, Inlurio and Itovebi endocrine therapy, Jakafi polycythemia-vera sequencing, and prior therapy for chronic GVHD.
    • Interaction review: avoid potent CYP3A4 inhibitors with Dasatinib and Ergotamine; document review of prohibited or interacting medications for Ketoconazole and other products. Multiple anticholinergic and multiple CNS-active medication reviews are required where indicated, particularly for older adults.
    • Opioids: extended-release opioid authorization requires opioid experience, safe dosing based on opioid history, evaluation and monitoring for opioid-use disorder, and at least 30 days of extended-release opioid or one week of immediate-release opioid use unless the cancer, sickle-cell, terminal-condition, or palliative-care exception applies.
    Documentation Required

    Diagnostic, Biomarker, Laboratory, and Treatment Records

    Submit objective diagnostic confirmation and treatment records for disease-specific authorization. Requests lacking required molecular, laboratory, stage, timing, or specialist evidence may be denied.

    • Required molecular findings: document BCR-ABL/Philadelphia chromosome, RET rearrangement, ALK positivity, EGFR mutation, BRAF V600 mutation, MET exon-14 skipping mutation, HER2/ERBB2 mutation or amplification, FGFR alteration, FLT3-ITD, IDH1/IDH2, CSF1R, KIT, PIK3CA/AKT/PTEN, ESR1, BRCA/PALB2, TTR, and other product-specific molecular findings.
    • Diagnostic confirmation: document Gaucher, Fabry, cystinosis, alpha1-proteinase inhibitor deficiency, cystic fibrosis, hereditary angioedema, IgA nephropathy, IPF, ATTR-CM, vasculitis, pulmonary hypertension, central precocious puberty, narcolepsy, type 2 diabetes, postpartum depression, and oncology diagnoses using the required laboratory, biopsy, imaging, genetic, or standardized-scale evidence.
    • Stage and disease status: provide recurrent, advanced, metastatic, unresectable, residual, refractory, relapsed, progressive, chronic-phase, blast-phase, induction, consolidation, maintenance, or post-transplant status as required. Inlyta requires advanced, relapsed, or stage IV RCC; Cabometyx, Fotivda, Sorafenib, and GIST products require the applicable stage and prior-treatment evidence.
    • Laboratory records: submit ferritin for Deferasirox, platelet count for Vonjo, testosterone levels, pulmonary hemodynamics for Treprostinil, glucose and A1C records for diabetes products, renal and hepatic information where required, and pretreatment and response measurements for Sapropterin, Increlex, Droxidopa, and Vyndamax.
    • Treatment timing: document prior therapy, treatment line, chemotherapy timing, continuation response, maintenance prerequisites, and required duration. Leqembi requires 18 months of IV therapy before maintenance; Fulphila, Leukine, and Zarxio require administration at least 24 hours after chemotherapy; Terbinafine and Zolpidem have duration limits.
    Denial Risk

    Denial Risks, Exclusions, and Coverage Responsibility

    Authorization may be denied when an exclusion, prohibited combination, coverage-responsibility rule, or indication restriction applies. Resolve these issues and submit supporting documentation before requesting review.

    • Coverage exclusions and responsibility: Part D coverage is excluded when Part A or Part B coverage is available or responsible; apply Part D coordination denial rules and submit use-and-setting information. HER2 products, Pulmozyme, lidocaine products, tobramycin, treprostinil, Wyost, Xtrenbo, and Zirabev contain explicit Part A/B responsibility rules where applicable.
    • Drug and indication exclusions: Ivermectin is excluded for COVID-19 prevention or treatment; tadalafil BPH excludes erectile dysfunction; Mavyret and Vosevi exclude decompensated cirrhosis or moderate/severe hepatic impairment; Hereditary angioedema must be confirmed for Haegarda, Berinert, and Icatibant; Cabometyx, Cresemba, and oncology products are restricted to their listed indications and stages.
    • Prohibited combinations and interactions: Kalydeco and other CFTR products may not be combined with another CFTR potentiator; Trikafta and Orkambi have the specified CFTR-combination restriction; avoid potent CYP3A4 inhibitors with Dasatinib or Ergotamine; Toremifene is excluded with congenital or acquired QT prolongation, uncorrected hypokalemia, or uncorrected hypomagnesemia.
    • Insufficient evidence: deny or pend requests when HER2 indication or treatment requirements are not met, hereditary angioedema is not confirmed, oncology disease or treatment history is insufficient, required molecular or laboratory findings are absent, clinical documentation is incomplete, or the requested use and setting are not established.
    • Duration and topical-use restrictions: restrict Terbinafine to the approved duration and non-continuous use; restrict topical products to the permitted duration and use; apply high-risk medication thresholds and the zolpidem annual limit.
    Note

    Provider Submission Checklist and Final Denial-Risk Review

    Before finalizing a request, verify that the provider has completed all required actions for the applicable product, indication, and benefit. The following cross-cutting checks consolidate additional denial-risk rules.

    • Confirm the indication and setting: identify the precise disease, stage, biomarker, treatment line, regimen, route, site of care, and whether the request is initial, continuation, maintenance, induction, consolidation, or post-transplant therapy.
    • Confirm specialist requirements: verify CF specialist involvement for cystic-fibrosis therapy, IPF specialist involvement for pirfenidone, pulmonology for Pulmozyme, endocrinology for Signifor, immunology/allergy/rheumatology for Haegarda, Berinert, and Icatibant, and required oncology or hematology involvement for oncology products.
    • Confirm prerequisites: verify drug-specific prerequisite therapy, topical corticosteroid prerequisite, anticonvulsant and Xcopri prerequisite, antidepressant prerequisite, DMARD or TNF-inhibitor prerequisite, triptan prerequisite, 5-ASA prerequisite, generic alternatives, prior EGFR or ROS1 therapy, GIST prior therapy, oncology sequencing, and continuation response.
    • Confirm safety attestations: review high-risk medication benefit-risk acknowledgment, older-adult anticholinergic and CNS-active medication burden, opioid-experience and monitoring requirements, cardiac/electrolyte exclusions, hepatic impairment, CYP3A4 interactions, and prohibited CFTR combinations.
    • Confirm required records: submit diagnostic and treatment documentation, laboratory and molecular findings, biomarker and stage evidence, specialist notes, baseline measurements, response measures, chemotherapy timing, Part A/B responsibility information, and standardized postpartum-depression or other diagnostic scales when applicable.
    • Final denial-risk check: do not request coverage when the indication is excluded, a prohibited combination is present, the required disease confirmation is absent, the required prior therapy has not been tried or appropriately excepted, or Part A/B coverage is available.
    Treprostinil hemodynamic thresholdsMean pulmonary arterial pressure greater than 20 mmHg; pulmonary capillary wedge pressure 15 mmHg or less; pulmonary vascular resistance greater than 2 Wood units
    CFTRCystic fibrosis transmembrane conductance regulator.